# Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

> **NCT02384317** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 7 (actual)

## Conditions studied

- Immunoglobulin A Nephropathy

## Interventions

- **DRUG:** CCX168

## Key facts

- **NCT ID:** NCT02384317
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-27
- **Primary completion:** 2015-09-13
- **Final completion:** 2018-06-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02384317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02384317, "Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02384317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*